Veno-occlusive disease of the liver, referred to as sinusoidal obstruction syndrome (SOS), is a severe complication of allogeneic hematopoietic SCT (allo-HSCT). The condition is characterized by hyperbilirubinemia, fluid retention and painful hepatomegaly presenting 1 month after HSCT. SOS occurs in 5.3% of HSCTs, and severe cases rapidly deteriorate to multiple organ failure with an overall fatality rate of 18.4%. 1 Usually, ursodeoxycholic acid (UDCA) and heparin are used to prevent SOS.
transplantation to prevent SOS. Engraftment was achieved on day 18 after transplantation. Levels of sICAM1 and sELAM1 improved to 404 and 10.5 ng/mL, respectively, on day 21 after the initiation of rhTM. However, these levels increased again, along with the concentration of serum fibrin degradation products, after cessation of rhTM ( Figure 1 ). Peripheral blood smears showed few fragmentocytes. Complications of allo-HSCT, such as SOS, aGVHD and thrombotic microangiopathy, were not observed. The patient was discharged on day 74 after transplantation. Although he had been making steady progress until day 212 after transplantation, he developed refractory chronic GVHD and iron overload. He suddenly died of septic shock on day 288 after transplantation, and immunosuppressive therapy was suspected to be the cause of sepsis.
The pathogenesis of SOS is based on endothelial damage, involving the loss of sinusoidal EC fenestration, the appearance of gaps in the sinusoidal EC barrier and dissection of the endothelial lining by the penetration of RBCs into the space of Disse beneath the ECs. Preparative regimens damage ECs and are the proximate cause of SOS. 3 It has been reported that high pre-transplant levels of sICAM1 were increased further by conditioning, especially among SOS patients. 4, 5 Recombinant hTM (Asahi Kasei Pharma, Tokyo, Japan) has been developed as a drug for the treatment of disseminated intravascular coagulation (DIC) in Japan. 6 Recombinant hTM is an endothelial anticoagulant cofactor that promotes the thrombin-mediated formation of activated protein C and is used to treat DIC. 6 It also has protective effects for ECs, one of which is the blocking of apoptosis of ECs by activated protein C. 7 Nomura et al. 8 reported that rhTM significantly suppressed the increase in the levels of sICAM1 and sELAM1 after allo-HSCT.
In this case, sICAM1 on the day prior to transplantation was almost at the same high level as those previously reported for SOS patients (median = 585 ng/mL). 4 Both sICAM1 and sELAM1 levels were ameliorated by the administration of rhTM, and increased again after cessation of rhTM. Therefore, rhTM might heal endothelial damage. Ikezoe et al. 9 reported the possible involvement of rhTM in protecting ECs from injury through the successful treatment of two SOS patients with rhTM.
In conclusion, rhTM may be useful for protecting ECs in allo-HSCT patients with risk factors for SOS and high serum levels of adhesion molecules associated with vascular endothelial injury prior to transplantation. 
